People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| GENVAULT Corp | — | Biotechnology | Series A | $20.4M | $245.9M | 2009 |
John S. Spilman at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John S. Spilman on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Benjamin S. Schapiro | 1 | 4 |
| Paul J Mirabella | 1 | 3 |
| James C. Blair, Ph.D. | 1 | 2 |
| David Wellis, Ph.D. | 1 | 2 |
| Erik J. Holmlin | 1 | 1 |
| Jay R. Flatley | 1 | 1 |
| William R. Brody, M.D., Ph.D. | 1 | 1 |
| Jay S. Flatley | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.